FDA to Review Lynparza Extension for Certain Advanced Breast Cancer Patients

FDA to Review Lynparza Extension for Certain Advanced Breast Cancer Patients
The U.S. Food and Drug Administration (FDA) will review AstraZeneca and Merck‘s application seeking the extension of Lynparza (olaparib) tablets for the treatment of HER-negative metastatic breast cancer patients whose tumors carry a germline mutation in the BRCA gene. The supplemental new drug application, meant for patients who have already received chemotherapy, has been granted

Knowledge is power when living with breast cancer.

Get access to the web’s leading Breast Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *